fda glp 1 shortage What Changed? The FDA's Clarification on Compounded GLP-1 Drugs Compounding US FDA's Problems: The

The complexity of lipidated peptide impurity profiles, as the January 2026 Analytical Scientist review documented, requires orthogonal analytical methods capable of separating and characterising species that differ by a single amino acid residue or by the presence or absence of a single linker modification

87% report success in their first month

Considering a meal delivery service to pair with your weight loss journey

Figure 1: FDA Approved Incretin Mimetic (GLP-1 and dual agonist) Diabetes and Obesity Products (as of December 2023) The Future of Incretin Mimetics in Diabetes and Obesity Looking Forward GLP-1 Clinical Development Pipeline Looking Forward GLP-1 Clinical Development Pipeline While Novo Nordisk and Eli Lilly dominate todays market, the success of incretin mimetics has attracted greater interest and investment, with a slew of potential new players aiming to enter and carve out their own space

M.MoadelT.SistiA

Print at home or use on your phone/tablet